MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma

INTRODUCTION: Multiple myeloma is a malignancy of plasma cells with around 6000 new cases per year in the UK. Cyclophosphamide plus prednisolone is considered a standard of care for disease and symptom control in the advanced relapsed or refractory myeloma setting within the UK NHS. The selective nu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kendall, Jessica, Hall, Andrew, Roberts, Sadie, Brown, Sarah, Boyd, Kevin, Auner, Holger W, Garg, Mamta, Kaiser, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615969/
https://www.ncbi.nlm.nih.gov/pubmed/36288835
http://dx.doi.org/10.1136/bmjopen-2022-062504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9615969/
https://www.ncbi.nlm.nih.gov/pubmed/36288835
http://dx.doi.org/10.1136/bmjopen-2022-062504

Ejemplares similares